Vesalio has successfully secured a Class A financing round. The company claims this funding will be utilised to support its ongoing US Investigational Device Exemption (IDE) stroke study, establish US infrastructure, scale international business, and expand its innovative product portfolio—including the proprietary NeVa platform, which was designed to consistently achieve first-pass recanalisation in acute ischaemic stroke by effectively removing all types of neurovascular clots from a patient’s anatomy.
“Vesalio welcomes our new investment partners and is thankful for the continued participation from our early investors in this round,” said Vesalio CEO Steve Rybka. “The funding allows us to assertively push toward the next key milestones for both US and global markets in neurovascular, as well as other specialties where our technology will benefit patients.”
US medical device company Vesalio recently completed a US Food and Drug Administration (FDA)-approved IDE study for the treatment of vasospasm, and is also currently enrolling patients in an FDA IDE study for ischaemic stroke that is expected to conclude in early-2022.
The Class A funding round, which was led by Chattanooga-headquartered venture capital firm Solas BioVentures, included participation from both new and existing investors. “We are pleased to partner with Vesalio as they drive the clinically proven NeVa thrombectomy platform towards US market entry for stroke,” said David Adair, co-founder and managing director of Solas BioVentures. “We are equally excited about the first-to-market opportunities in vasospasm treatment along with the cutting-edge technologies they have in the pipeline.”
